SCHEMBL19851008

SCHEMBL19851008

CC(Sc1nc2ncccc2n1-c1ccc(C2CC2)c2ccccc12)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 18/20 1.00
CYP2C9 P11712 4/20 1.00
CYP2C19 P33261 3/20 1.00
CYP3A4 P08684 2/20 0.70
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
SLC22A11 Q9NSA0 1/20 0.43
PTGS2 P35354 1/20 0.39
SLC2A9 Q9NRM0 1/20 0.38
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29678107 1.00 SLC22A12 (1.00) SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2
SCHEMBL19851130 0.89 SLC22A12 (0.80) SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2
SCHEMBL19851009 0.88 SLC22A12 (0.79) SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2
SCHEMBL19851020 0.85 SLC22A12 (0.74) SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2
SCHEMBL25955123 0.83 SLC22A12 (0.71) SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2
SCHEMBL19851077 0.83 SLC22A12 (0.76) SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2
SCHEMBL25955012 0.83 SLC22A12 (1.00) SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2
SCHEMBL19851129 0.83 SLC22A12 (0.70) SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2
SCHEMBL19851106 0.82 SLC22A12 (1.00) SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2
SCHEMBL23954470 0.82 SLC22A12 (0.69) SLC22A12CYP2C9CYP2C19CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114685485-B Synthesis method of pyridoimidazole thiopropionic acid anti-gout compound 山东海雅医药科技有限公司 2024-03-26 CN disclosed
CN-115385907-B Room-temperature stable crystal form of pyridoimidazole thiopropionic acid anti-gout compound and preparation method thereof 山东海雅医药科技有限公司 2024-01-16 CN disclosed
CN-114685485-A Synthesis method of pyridylimidazole thiopropionic acid anti-gout compound 山东海雅医药科技有限公司 2022-07-01 CN disclosed
EP-3495362-B1 IMIDAZOPYRIDINE THIOGLYCOLIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF UNIV SHANDONG (CN) 2021-10-27 EP disclosed
US-10399978-B2 Imidazopyridine thioglycolic acid derivatives as potent inhibitors of human urate transporter 1 SHANDONG UNIVERSITY (CN) 2019-09-03 US disclosed
US-20190225606-A1 Novel Imidazopyridine Thioglycolic Acid Derivatives as Potent Inhibitors of Human Urate Transporter 1 SHANDONG UNIVERSITY (CN) 2019-07-25 US disclosed
EP-3495362-A1 IMIDAZOPYRIDINE THIOGLYCOLIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shandong University (CN) 2019-06-12 EP disclosed
WO-2018023851-A1 IMIDAZOPYRIDINE THIOGLYCOLIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 山东大学 2018-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225606-A1 Novel Imidazopyridine Thioglycolic Acid Derivatives as Potent Inhibitors of Human Urate Transporter 1 SLC29A1, SLC28A1, SLC5A1 SLC22A12 118/4885CYP2C9 292/4885CYP2C19 1044/4885
US-10399978-B2 Imidazopyridine thioglycolic acid derivatives as potent inhibitors of human urate transporter 1 SLC29A1, SLC28A1, SLC5A1 SLC22A12 163/4885CYP2C9 254/4885CYP2C19 907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.